text:
EX-99.1
15
exhibit14.htm
EX-99.1
EX-99.1
Contact: Jill Swartz
NNN Realty Advisors, Inc.
1551 N. Tustin Avenue, Suite 300
Santa Ana, California 92705
714-667-8252 ext. 251
jswartz@nnnrealtyadvisors.com
NNN HEALTHCARE/OFFICE REIT ACQUIRES
2750 MONROE BOULEVARD IN VALLEY FORGE, PENNSYLVANIA
Santa Ana, Calif., September 14, 2007
- NNN Healthcare/Office REIT, Inc. has acquired 2750 Monroe
Boulevard in Valley Forge, Pennsylvania. The acquisition closed on September 10, 2007.
2750 Monroe Boulevard is a two-story single-tenant office building totaling nearly 106,000 square
feet, as well as an accessory building used for storage that totals more than 3,400 square feet, on
a 10.5-acre parcel in the Valley Forge Corporate Center. Located approximately 25 miles northwest
of downtown Philadelphia, 2750 Monroe Boulevard was built in 1985 and extensively renovated in
2001. The building has 540 parking spaces allocated to it for a ratio of more than five spaces per
1,000 rentable square feet.
The facility is completely leased through April 2011 to Quest Diagnostics, Inc. (NYSE: DGX), a
Fortune 500 company that is one of the nation's leading providers of diagnostic testing,
information and services. Quest Diagnostics utilizes the building as its National Revenue Services
Center, which provides bill management and accounting for all of Quest Diagnostics' domestic
operations. Quest Diagnostics reported net revenue of more than $6.2 billion in 2006, and has a
current market capitalization in excess of $10.5 billion.
"2750 Monroe Boulevard is a high-quality addition to the NNN Healthcare/Office REIT portfolio of
properties", explained Danny Prosky, vice president of acquisitions for NNN Healthcare/Office REIT.
"We have a superior tenant in place and have further diversified our holdings with this
acquisition".
NNN Healthcare/Office REIT purchased 2750 Monroe Boulevard from Lexington Valley Forge L.P., which
was represented by Carl Nielson of Grubb & Ellis Company. Financing was provided by LaSalle Bank
National Association, arranged by
Brad Feine. Asset management services will be provided
by NNN Realty Advisors, Inc.
As of August 31, 2007, NNN Healthcare/Office REIT has sold approximately 14.3 million shares of its
common stock for more than $142.4 million through its initial public offering, which began in the
third quarter of 2006.
- MORE -
2 - 2 - 2 NNN Healthcare/Office REIT Acquires 2750 Monroe Boulevard
NNN Healthcare/Office REIT offers a monthly distribution of 7.25 percent per annum and has made
twelve other geographically-diverse acquisitions:
.
St. Mary Physicians Center in Long Beach, California;
.
Kokomo Medical Office Park in Kokomo, Indiana;
.
1 and 4 Market Exchange in Columbus, Ohio;
.
Gwinnett Professional Center in Lawrenceville, Georgia;
.
Triumph Hospital Northwest and Triumph Hospital Southwest in Greater Houston, Texas;
.
Thunderbird Medical Plaza in Glendale, Arizona;
.
Shakerag Medical Center and Yorktown Medical Center in Fayette County, Georgia;
.
Commons V Medical Office Building in Naples, Florida;
.
Lenox Office Park Building G in Memphis, Tennessee;
.
The Gallery Professional Building in St. Paul, Minnesota;
.
Crawfordsville Medical Office Park and Athens Surgery Center in Crawfordsville, Indiana;
and
.
Southpointe Office Parke and Epler Parke I in Indianapolis, Indiana.
Including the purchase of 2750 Monroe Boulevard, NNN Healthcare/Office REIT has acquired a
portfolio of properties valued in excess of $231 million.
NNN Realty Advisors, Inc., a nationwide commercial real estate asset management and services firm,
is the sponsor of NNN Healthcare/Office REIT, Inc. NNN Realty Advisors and affiliates manage a
growing portfolio of more than 39.1 million square feet of real estate, including approximately
10,100 apartment units, with a combined market value approaching $5.3 billion. NNN Realty Advisors
and affiliates are currently buying and selling properties throughout the United States, offering a
full range of commercial real estate investments, including tenant-in-common (TIC) programs for
investors structuring tax-deferred (like-kind) exchanges under Section 1031 of the Internal Revenue
Code, real estate investment trusts (REITs), value added property funds, and institutional
investments.
###

text: NNN HEALTHCARE/OFFICE REIT

text: NNN Healthcare/Office REIT, Inc.

text: NNN Healthcare/Office REIT

text: Danny Prosky

text: NNN Healthcare/Office REIT

text: NNN Healthcare/Office REIT

text: Lexington Valley Forge L.P.

text: Grubb & Ellis Company

text: NNN Healthcare/Office REIT

text: NNN Healthcare/Office REIT

text: NNN Healthcare/Office REIT

text: NNN Healthcare/Office REIT

text: NNN Healthcare/Office REIT, Inc.


dataset: buster

text:
EX-99.1
3
a10-14873_1ex99d1.htm
EX-99.1
Exhibit 99.1
CONTACT:
William
George
675 Bering Drive, Suite 400
Chief
Financial Officer
Houston, Texas 77057
(713)
830-9600
713-830-9600
Fax: 713-830-9696
FOR IMMEDIATE RELEASE
COMFORT SYSTEMS USA
ANNOUNCES ACQUISITION
- Acquires ColonialWebb Contractors Company in Virginia -
- Discusses Second Quarter Earnings -
Houston, TX - July 28, 2010 - Comfort Systems USA, Inc.
(NYSE: FIX),
a leading provider of commercial, industrial and
institutional heating, ventilation and air conditioning ("HVAC") services,
today announced that it has acquired ColonialWebb Contractors Company ("ColonialWebb")
headquartered in Richmond, Virginia.
ColonialWebb
is a large and important regional
contractor with its principal operations in Richmond and Norfolk, Virginia. ColonialWebb engages in a broad range of
mechanical contracting projects, HVAC service and industrial refrigeration,
primarily in Virginia, North Carolina and South Carolina. Initially ColonialWebb is expected to
contribute annualized revenues of approximately $180 million to $190 million at
profitability levels that are expected to be roughly equivalent to those
generally earned by Comfort Systems USA operations. Because of the amortization of intangibles and
other costs associated with the transaction, the acquisition is not expected to
be materially accretive to earnings per share during the first 12 to 18 months
after the acquisition.
Bill
Murdy, Comfort Systems USA's Chief Executive Officer, commented, "We are
extremely pleased that ColonialWebb is joining Comfort Systems USA. ColonialWebb has a long history of excellence
throughout the mid-Atlantic region and will immediately become our largest
subsidiary. With excellent capabilities,
systems, resources and leadership at every level, ColonialWebb will continue to
be a significant factor in the mechanical contracting and service industries
overall, and we expect that, over time, interaction between our existing
companies and ColonialWebb will strengthen and improve all of Comfort Systems USA".
The
Company reiterated that its second quarter earnings release remains scheduled
for close of business on August 2, 2010, with the analyst call the
following day, August 3, 2010, at 10:00 a.m. Central Time. Details of the call are included below.
Mr. Murdy
continued, "Earnings from our core operations were well within the expected
ranges during the second quarter of 2010.
As we reviewed our results, the Company decided that due to a period of
weak results at one of our operations, it was appropriate to formally test the
goodwill balances associated with that operation. As a result of that review, the Company
expects that it will incur a noncash impairment of goodwill of approximately
$5.7 million in the second quarter, so earnings per share calculated after
giving effect to that impairment will be reduced by $0.09. As a result of this noncash impairment,
reported earnings per share for the quarter will most likely be in the very low
single digit range." Mr. Murdy
concluded, "As we have discussed in the past, the cyclical nature of our
industry results in the likelihood that from time to time we will incur
individual goodwill impairments. Despite
the noncash impairment of these intangible
assets,
our operations and outlook remain solid, and we look forward to discussing our
ColonialWebb acquisition and our results during our analyst call next week".
As
previously announced, the Company will host a conference call to discuss its
financial results and position in more depth on Tuesday, August 3, 2010 at
10:00 a.m. Central Time. The
call-in number for this conference call is 1-888-713-4218 and enter 15208700 as
the passcode. Participants may
pre-register for the call at https://www.theconferencingservice.com/prereg/key.process?key=PY4VJDERQ. Pre-registrants will be issued a pin number
to use when dialing into the live call which will provide quick access to the
conference by bypassing the operator upon connection. The call can also be accessed on the Company's
website at
www.comfortsystemsusa.com
under the Investor tab. A replay of the
entire call will be available until 6:00 p.m. Central Time, Tuesday, August 10,
2010 by calling 1-888-286-8010 with the conference passcode of 79634038, and
will also be available on our website on the next business day following the
call.
Comfort
Systems USAÒ is a premier provider of business solutions
addressing workplace comfort, with 84 locations in 74 cities around the
nation. For more information, visit the
Company's website at
www.comfortsystemsusa.com.
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on the current
plans and expectations of future events of Comfort Systems USA, Inc. and
involve risks and uncertainties that could cause actual future activities and
results of operations to be materially different from those set forth in the
forward-looking statements. Important
factors that could cause actual results to differ include, among others, the
use of incorrect estimates for bidding a fixed-price contract, undertaking
contractual commitments that exceed our labor resources, failing to perform
contractual obligations efficiently enough to maintain profitability, national
or regional weakness in construction activity and economic conditions,
financial difficulties affecting projects, vendors, customers, or
subcontractors, our backlog failing to translate into actual revenue or
profits, difficulty in obtaining or increased costs associated with bonding and
insurance, impairment to goodwill, errors in our percentage-of-completion
method of accounting, the result of competition in our markets, our
decentralized management structure, shortages of labor and specialty building
materials, retention of key management, seasonal fluctuations in the demand for
HVAC systems, the imposition of past and future liability from environmental,
safety, and health regulations including the inherent risk associated with
self-insurance, adverse litigation results and other risks detailed in our
reports filed with the Securities and Exchange Commission. A further list and description of these
risks, uncertainties and other factors are discussed under "Item 1A. Company
Risk Factors" in the Company's Annual Report on Form 10-K for the year
ended December 31, 2009. These
forward-looking statements speak only as of the date of this filing. Comfort Systems USA, Inc. expressly
disclaims any obligation or undertaking to release publicly any updates or
revisions to any forward-looking statement contained herein to reflect any
change in our expectations with regard thereto or any change in events,
developments, conditions or circumstances on which any such statement is based.

label: organization

text: COMFORT SYSTEMS USA

text: ColonialWebb Contractors Company

text: Comfort Systems USA, Inc.

text: ColonialWebb Contractors Company

text: Comfort Systems USA

text: Comfort Systems USA

text: Comfort Systems USA

text: Comfort Systems USA

text:
Comfort
Systems USA

text: Comfort Systems USA, Inc.

text: Comfort Systems USA, Inc.

source_dataset: expertai/BUSTER

annotation_scope: BUSTER company-role spans plus reviewed organization, fund, person, and event additions with document-local surface projection; annotations remain non-exhaustive


text:
EX-99.1
6
d759374dex991.htm
EX-99.1
EX-99.1
Exhibit 99.1
Oncternal Therapeutics Completes Reverse Merger with GTx, Inc.
- Shares of Oncternal to commence trading on Nasdaq under new ticker symbol ONCT
on June 10, 2019 -
SAN DIEGO
- June
10
- Oncternal Therapeutics, Inc., (Nasdaq: ONCT) a clinical-stage biotechnology company developing potential
first-in-class
product candidates for cancers with critical unmet medical need, today announced that the reverse merger with GTx, Inc., closed on June 7, 2019. The combined company will operate under the name Oncternal Therapeutics, Inc., and its shares will
commence trading on the Nasdaq stock exchange on June 10, 2019, under the ticker symbol "ONCT".
"We believe that the closing of the
merger signifies a transformative event that will provide Oncternal with the opportunity to achieve its next level of corporate growth as we continue to advance our promising oncology drug candidates through development", said James Breitmeyer,
M.D., Ph.D., Oncternal's President and CEO. "We recently presented updated interim data from an ongoing clinical study of our investigational monoclonal antibody, cirmtuzumab, at the American Society of Clinical Oncology (ASCO) Annual
Meeting, and we look forward to achieving a number of exciting milestones in our development programs in the future".
Pursuant to the merger, all of
Oncternal's outstanding shares of common stock and securities convertible into or exercisable for Oncternal's common stock were converted into GTx common stock and securities convertible into or exercisable for GTx common stock.
Immediately following the completion of the merger, the former stockholders of Oncternal held approximately 77.5% of the outstanding shares of common stock of the combined company. In addition to retaining an ownership interest representing
approximately 22.5% of the outstanding shares of common stock of the combined company, the GTx stockholders of record as of immediately prior to the effective time of the merger received contingent value rights (CVR) entitling the holders to
receive, in the aggregate, 75% of any net proceeds derived from the grant, sale or transfer of rights to GTx's selective androgen receptor degrader (SARD) and selective androgen receptor modulator (SARM) technology during the term of the CVR
and, if applicable, to receive royalties on the sale of any SARD products by the combined company during the term of the CVR.
Oncternal's
development pipeline consists of the following programs:
.
Oncternal's lead program, cirmtuzumab, is an investigational, potential
first-in-class
anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) monoclonal antibody. Cirmtuzumab is currently in a Phase 1/ 2 clinical trial in combination with ibrutinib for the treatment of
chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Last week, the company presented interim data from the study at the ASCO 2019 Annual Meeting. In addition, an investigator-initiated Phase 1 clinical trial of cirmtuzumab in
combination with paclitaxel for women
with metastatic breast cancer is being conducted at the University of California San Diego (UC San Diego) School of Medicine. The California Institute for Regenerative Medicine (CIRM) has
provided funding to support the cirmtuzumab development program.
.
TK216, an investigational, potential
first-in-class
small molecule designed to inhibit the biological activity of E26 transformation-specific (ETS) oncoproteins, is being evaluated alone and in combination
with vincristine in a Phase 1 clinical trial in patients with relapsed or refractory Ewing sarcoma, a rare pediatric cancer. Oncternal is also planning a Phase 1 clinical trial in patients with relapsed acute myeloid leukemia (AML).
.
A
ROR-1
targeted chimeric antigen receptor
T-cell
(CAR-T)
program is in preclinical development in collaboration with UC San Diego for hematologic cancers and solid tumors.
About Oncternal Therapeutics
Oncternal Therapeutics is a
clinical-stage biopharmaceutical company focused on developing a diverse pipeline of product candidates for the treatment of cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways
implicated in cancer progression. The pipeline includes cirmtuzumab, a monoclonal antibody designed to inhibit the ROR1 receptor that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of CLL and
MCL,
and TK-216,
a small-molecule compound that is designed to inhibit
ETS-family
oncoproteins, which is being evaluated in a Phase 1 clinical trial alone and in
combination with vincristine as a treatment for Ewing sarcoma, a rare pediatric cancer. In addition, Oncternal has
a CAR-T
product candidate that targets ROR1, which is currently in preclinical
development as a potential treatment for hematologic cancers and solid tumors. More information is available at
www.oncternal.com
.
Forward-Looking Information
Oncternal cautions you that
statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may", "will,"
"should", "expect", "plan", "anticipate", "could", "intend", "target", "project", "contemplates", "believes", "estimates,"
"predicts", "potential" or "continue" or the negatives of these terms or other similar expressions. These statements are based on the Company's current beliefs and expectations. Forward looking statements include
statements regarding Oncternal's beliefs, goals, intentions and expectations, and include statements regarding its belief that the transaction between GTx and Oncternal will provide the combined company with the opportunity to achieve its next
level of corporate growth; the ability of the combined company to continue to advance its product candidates through the development process and achieve potential clinical development milestones in the future; the potential for any payments to
former GTx, Inc. securityholders under the CVR; the potential for cirmtuzumab or TK216 drug candidates to be
first-in-class,
if approved; and other statements that are
not historical fact. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation: risks related to
Oncternal's ability to obtain sufficient additional capital to continue to advance the
company's product candidates and preclinical programs; unexpected costs, charges or expenses that may result from the transaction; risks associated with potential changes to business
relationships that may result from the announcement or completion of the transaction; uncertainties associated with the clinical development and regulatory approval of Oncternal's product candidates, including potential delays in the
commencement, enrollment and completion of clinical trials; the risk that interim results of clinical trials do not necessarily predict final results and that one or more of the clinical outcomes may materially change as patient enrollment
continues, following more comprehensive reviews of the data, and as more patient data become available; the risk that unforeseen adverse reactions or side effects may occur in the course of developing and testing product candidates; risks associated
with the failure to realize any value from product candidates and preclinical programs being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; and
risks associated with the possible failure to realize certain anticipated benefits of the transaction, including with respect to future financial and operating results. All forward-looking statements in this press release are current only as of the
date hereof and, except as required by applicable law, Oncternal undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or
otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Oncternal Contacts:
Investors
Richard Vincent
858-434-1113
rvincent@oncternal.com
Media
Jason Spark
619-849-6005
jason@canalecomm.com

text: Oncternal Therapeutics

text: GTx, Inc.

text: Oncternal Therapeutics, Inc.

text: GTx, Inc.

text: Oncternal Therapeutics, Inc.

text: Oncternal Therapeutics

text: Oncternal Therapeutics

text: GTx, Inc.


text:
EX-99.1
3
exh991pressrelease.htm
EXHIBIT 99.1
Exhibit
Soleno Therapeutics Announces Sale of Non-Strategic Assets to Flexicare, Inc.
REDWOOD CITY, Calif., July 24, 2017 - Soleno Therapeutics, Inc. (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the sale of one of its non-strategic subsidiaries, NeoForce, Inc., which manufacturers and promotes a range of innovative pulmonary resuscitation solutions in the neonatal market, to Flexicare, Inc., a privately-held, leading UK-based manufacturer of airway management, anesthesia and critical care medical devices.
"We have recently refocused our business on the development and commercialization of novel therapeutics for the treatment of rare diseases", said Anish Bhatnagar, M.D., Chief Executive Officer of Soleno Therapeutics. "As such, we are pleased to monetize these non-strategic assets, which allows us to focus our resources on our lead product candidate, Diazoxide Choline Controlled-Release (DCCR), currently in clinical development for Prader-Willi syndrome (PWS), a rare and complex genetic neurobehavioral disorder affecting appetite, growth, metabolism, cognitive function, and behavior. We expect to initiate a Phase III clinical trial for DCCR by the end of 2017".
"The acquisition of NeoForce advances Flexicare's mission of providing high quality medical devices, expanding its neonatal portfolio and footprint both in the US and internationally. We will support NeoForce's ambition to become a leading supplier of neonatal resuscitation devices, caring for our most vulnerable of patients. This is a long-term strategic investment in a growing sector that we are actively pursuing and will continue to invest in to realize our full potential within this market segment", said Ghassem Poormand, President Flexicare, Inc.
About Soleno Therapeutics, Inc.
Soleno Therapeutics, Inc. (Soleno) is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company is currently advancing its lead candidate, DCCR, a once-daily oral tablet for the treatment of PWS, into a Phase III clinical development program at the end of 2017. PWS is a rare and complex genetic neurobehavioral/metabolic disorder affecting appetite, growth, metabolism, cognitive function and behavior. DCCR has received Orphan Drug Designation from the US FDA for the treatment of PWS. Diazoxide choline controlled-release tablet is a novel, proprietary controlled-release, crystalline salt formulation of diazoxide, which is administered once-daily. In the PWS pilot study, DCCR showed promise in addressing the hallmark symptoms of PWS, most notably hyperphagia. Soleno, through its wholly owned subsidiary, Capnia, Inc., continues to market Capnia's innovative medical devices, including the CoSense® End-Tidal Carbon Monoxide (ETCO) monitor, which measures ETCO and is used by hospitals to detect hemolysis in newborns.
For more information, please visit www.soleno.life.
About Flexicare
Flexicare is a privately owned, leading manufacturer and supplier of medical devices with over 40 years of experience in the healthcare sector. Headquartered in the UK, Flexicare is a major supplier to the NHS and private institutions in the UK, as well as having an international presence in over 105 countries through its appointed distributors and supported by its own subsidiaries in the US, Middle East, India, China, Japan, Australia and Malaysia.
For more information, please visit www.flexicare.com
Forward-Looking Statements
This press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our ability to initiate the Phase III clinical development program of DCCR in PWS by the end of 2017. We may use terms such as "believes", "estimates", "anticipates", "expects", "plans", "intends", "may", "could", "might", "will", "should", "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this presentation. As a result of these factors, we cannot assure you that the forward-looking statements in this presentation will prove to be accurate. Additional factors that could materially affect actual results can be found in Capnia's Form 10-Q filed with the Securities and Exchange Commission on May 11, 2017, including under the caption titled "Risk Factors." Capnia expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.
Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578

text: Soleno Therapeutics

text: Flexicare, Inc.

text: Soleno Therapeutics, Inc.

text: NeoForce, Inc.

text: Flexicare, Inc.

text: Soleno Therapeutics

text: NeoForce

text: NeoForce

label: person

text: Ghassem Poormand

text: Flexicare, Inc.

text: Soleno Therapeutics, Inc.

text: Soleno Therapeutics, Inc.


text:
EX-99.2
7
miller_ex99z2.htm
PRESS RELEASE
Press Release
EXHIBIT 99.2
FOR IMMEDIATE RELEASE:
Announces additional Board Directors and President.
HUNTSVILLE, TN - December 16, 2009 -
Miller Petroleum, Inc. dba Miller Energy Resources ("Miller"), (OTC BB: MILL:OB) announced today the appointment of Ford F. Graham as Vice-Chairman of the Board of Directors of Miller and as President of the Company. Mr. Graham is a Managing Partner of Vulcan Capital and the Vulcan Partners family of private equity funds and companies. Mr. Graham has over 25 years experience as a private equity investor and an investment banker in the energy and natural resources sectors. Mr. Graham has previously worked for Solomon Smith Barney, Bear Stearns and Dean Witter and the Regan Administration.
Mr. Graham has specialized in creating value for natural resources companies through opportunistic acquisitions, innovative financings, and carefully managed development of natural resource assets. Mr. Graham noted, "I am excited about the opportunity to work with Miller in this time of growth and look forward to helping the Company become one of the most valuable natural resource firms in the U.S. Vulcan has worked closely with Miller for the past several years and we are thrilled to see some of the fruits of our long term strategic vision coming to pass. We think the future will hold even more promise as we execute on our plan of development and growth" Mr. Graham holds an A.B. in Geology and Geophysical Sciences from Princeton University, a J.D. from Tulane Law School and an M.B.A. from the A.B. Freeman School of Business at Tulane University.
Miller also announced the appointment of David Hall to the Board of Miller. Mr. Hall was the former Vice President and General Manager of Alaska Operations, Pacific Energy Resources LTD. Before that time, he served as the Production Foreman and Lead Operator in Alaska for Forest Oil Corp, rising to Production Manager for all of Alaska operation for Forest Oil. Mr. Hall has worked with the acquired Alaska assets since their construction began in 1991. He brings over 20 years of experience to Miller. Mr. Hall holds a Master's Degree in Industrial Engineering and a Bachelor's Degree in Electrical Engineering from Rochville University.
Scott Boruff, Miller's CEO noted, "We are very excited to have Mr. Graham and Mr. Hall join us on the board of Miller. Mr. Graham has been instrumental in the execution of our strategy to
grow our Company and in our Alaska acquisition. Mr. Hall's expertise and contributions in our new Alaska subsidiary will be critical to the success of our plan of execution and delivering value to our shareholders. We welcome both Ford and David to the board and look forward to a long a prosperous relationship".
About Miller
Miller Energy Resources is a high-growth oil and natural gas exploration, production and drilling company operating in multiple exploration and production projects in North America. Miller's focus is in Cook Inlet, Alaska and in the heart of Tennessee's prolific and hydrocarbon-rich Appalachian Basin. Miller is a Tennessee registered company that has been in existence for over 40 years and been publicly traded for 12 years. It is the largest owner/operator of oil and gas wells in Tennessee with over 602 wells, over 54,500 net acres of lease holdings in Tennessee and 602,000 net acres in Alaska. Company chairman, Deloy Miller has a successful oil and gas track record spanning more than forty years in the Tennessee Basin. Since 1967, Miller has drilled and/or serviced over 5,200 wells.
Miller is one of the United States premier energy companies and is using its strategy of opportunistic growth combined with prudent development and management of exiting assets to maximize value for its shareholders.
Miller is headquarters in Huntsville, Tennessee with offices in Knoxville and New York City. The company is traded over the bulletin board with the symbol MILL.OB, MILL:US.
Statements Regarding Forward-Looking Information
This news release contains statements about oil and gas production and operating activities that may constitute "forward-looking statements" or "forward-looking information" within the meaning of applicable securities legislation as they involve the implied assessment that the resources described can be profitably produced in the future, based on certain estimates and assumptions. Forward-looking statements are based on current expectations, estimates and projections that involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those anticipated by Miller Energy Resources and described in the forward-looking statements. These risks, uncertainties and other factors include, but are not limited to, adverse general economic conditions, operating hazards, drilling risks, inherent uncertainties in interpreting engineering and geologic data, competition, reduced availability of drilling and other well services, fluctuations in oil and gas prices and prices for drilling and other well services, government regulation and foreign political risks, fluctuations in the US dollar and other currencies, the availability of sufficient capital to fund its anticipated growth, fluctuations in the prices of oil and gas, the competitive nature of its business environment, its dependence on a limited number of customers, its ability to comply with environmental regulations, changes in government regulations which could adversely impact its businesses well as other risks commonly associated with the exploration and development of oil and
gas properties. Additional information on these and other factors, which could affect Miller's operations or financial results, are included in Miller's reports on file with United States securities regulatory authorities. Miller Energy Resources' actual results could differ materially from those anticipated in these forward- looking statements as a result of a variety of factors, including those discussed in its periodic reports that are filed with the Securities and Exchange Commission and available on its Web site (www.sec.gov). All forward- looking statements attributable to Miller Energy Resources or to persons acting on its behalf are expressly qualified in their entirety by these factors. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. We assume no obligation to update forward-looking statements should circumstances or management's estimates or opinions change unless otherwise required under securities law.
For more information, please contact the following:
CONTACT:
William "Bill" Goodwin
Investor Relations
Miller Energy Resources
3651 Baker Highway
P.O. Box 130
Huntsville, Tennessee 37756
Phone: 423-663-9457
Fax: 423-663-9461
Web Site:
http://www.millerenergyresources.com

label: fund

text: Vulcan Capital

text: Vulcan Partners


text:
EX-99.1
4
exhibit_99-1pressrelease.htm
PRESS RELEASE ISSUED BY EUSA PHARMA, INC. DATED 05/09/08
exhibit_99-1pressrelease.htm
EXHIBIT
99.1
Press
Release
Source:
EUSA Pharma Inc
EUSA
Pharma Completes Acquisition Of Cytogen Corporation
Friday
May 9, 5:07 am ET
DOYLESTOWN,
Pennsylvania and OXFORD, England, May 9 /PRNewswire/ -- EUSA Pharma Inc
('EUSA'), a transatlantic specialty pharmaceutical company focused on oncology,
pain control and critical care, today announced that it has completed its
acquisition of Cytogen Corporation, following the approval of Cytogen's
shareholders at a special meeting on 8 May.
Under the
terms of the acquisition agreement, Cytogen shareholders will receive $0.62 per
share, valuing the company at $22.6 million. To meet the consideration, EUSA has
raised over $50 million in an investment round led by TVM Capital and supported
by EUSA's existing investors, Essex Woodlands, 3i, Goldman Sachs, Advent Venture
Partners, SV Life Sciences, NeoMed and NovaQuest. EUSA will now apply to delist
all Cytogen's issued shares from the NASDAQ stock exchange.
Cytogen
brings to EUSA three oncology and pain control products, a US specialty sales
force and an established commercial infrastructure. With the completion of the
acquisition, Cytogen will form a wholly-owned subsidiary of EUSA and will
operate under the EUSA name.
"Completing
our acquisition of Cytogen is particularly significant for EUSA as it also
completes our transatlantic growth platform, positioning us as a partner of
choice for further acquisitions and product in-licensing", said Bryan Morton,
Chief Executive of EUSA Pharma. "We now have a strong US commercialization
infrastructure to match our organization in Europe, which covers over 20
countries. We plan to rapidly integrate the Cytogen organization, allowing us to
compete with major players as we accelerate our search for additional specialty
products to leverage our infrastructure on both sides of the Atlantic. With a
growing portfolio of medicines, we plan to begin exploiting our transatlantic
platform with the launch of our US product Caphosol® in several European
territories".
About
EUSA Pharma Inc
EUSA
Pharma is a rapidly growing transatlantic specialty pharmaceutical company
focused on in-licensing, developing and marketing late-stage oncology, pain
control and critical care products. The company currently has nine products on
the market, including Caphosol® for the treatment of oral mucositis, a common
and debilitating side-effect of radiation therapy and high-dose chemotherapy,
ProstaScint® for imaging the extent and spread of prostate cancer, Quadramet®
for the treatment of pain in patients whose cancer has spread to the bones,
Erwinase® and Kidrolase® for the treatment of acute lymphoblastic leukemia, the
antibiotic surgical implant Collatamp® G, and Rapydan®, a rapid-onset anesthetic
patch which recently received Europe-wide approval. EUSA also has several
products in late-stage development, notably Collatamp® G topical, a gentamicin
impregnated collagen sponge for the prevention and treatment of infected skin
ulcers, and CollaRx® bupivacaine implant* for local post-surgical pain
control.
Founded
in 2006, EUSA Pharma is supported by a consortium of leading life science
capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs,
Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its
foundation, the company has raised over $275 million, and completed several
significant transactions, including the acquisitions of Cytogen Corporation,
Talisker Pharma Ltd, the French biopharmaceutical
company
OPi SA and the European antibiotic and pain control business of Innocoll
Pharmaceuticals Inc. As part of its rapid growth strategy the company has
established commercial infrastructure in the US, a pan-European presence
covering over 20 countries and a wider distribution network in a further 25
territories. EUSA Pharma plans to continue its aggressive program of
acquisitions and in-licensing within its specialist areas of medical and
geographic focus, in line with its ambitious target to create a rapidly growing
$1 billion company by the beginning of the next decade.
For more
information please visit
http://www.eusapharma.com
.
*CollaRx®
is a registered trademark of Innocoll Technologies Ltd.
Source:
EUSA Pharma Inc

text: EUSA PHARMA

text: EUSA Pharma Inc

text:
EUSA
Pharma

text: Cytogen Corporation

text: EUSA Pharma Inc

text: Cytogen Corporation

text: Cytogen

text: Cytogen

text: TVM Capital

override: fund

text: Essex Woodlands

text: Goldman Sachs

text:
Advent Venture
Partners

text: SV Life Sciences

text: NeoMed

text: NovaQuest

text: Cytogen

text: Cytogen

text: Cytogen

text: Cytogen

text: EUSA Pharma

text: Cytogen

text: EUSA Pharma Inc

text:
EUSA
Pharma

text: EUSA Pharma

text: TVM Capital

text: Essex Woodlands

text: Goldman Sachs

text: Advent Venture Partners

text: SV Life Sciences

text: NeoMed

text: NovaQuest

text: Cytogen Corporation

text: Talisker Pharma Ltd

text: EUSA Pharma

text: EUSA Pharma Inc


text:
EX-99.1
3
v227892_ex99-1.htm
Unassociated Document
Exhibit 99.1
MEDIA CONTACT:
Mark Brown
Vice President Marketing
mark.brown@dealertrack.com
(516)734-3887
INVESTOR CONTACT:
Elizabeth Besen
Director of Investor Relations
elizabeth.besen@dealertrack.com
(516) 734-3859
DealerTrack Completes Acquisition of eCarList
Lake Success, N.Y., July 6, 2011
- DealerTrack AAX, Inc., a subsidiary of DealerTrack Holdings, Inc. (Nasdaq: TRAK), today announced that it has completed the acquisition of substantially all of the assets of eCarList LLC, a leading provider of inventory management and merchandising solutions for automobile dealerships. The agreement to acquire eCarList was announced on May 25, 2011.
Based in Dallas, eCarList provides a full suite of inventory management and online marketing tools for the retail automotive industry, enabling dealers to appraise, price, and merchandise vehicle inventory online in real-time. eCarList's solutions and services are now part of the DealerTrack Inventory Solutions Group, which includes inventory management, inventory distribution, vehicle appraisal and pricing tools, mobile software, dealership health reporting, CRM, custom web design, and digital marketing solutions via an integrated Software as a Service (SaaS) platform. eCarList improves dealership productivity, inventory turn, sales, and profits for its clients by improving and simplifying the way in which inventory is managed, distributed, and viewed by consumers.
Mark F. O'Neil, chairman and chief executive officer of DealerTrack, commented, "The acquisition of eCarList will improve upon our industry-leading inventory management solution to the automotive retail market." O'Neil continued, "The combination of DealerTrack AAX's analytical and vehicle performance reporting tools along with eCarList's innovative merchandising solutions will help dealerships more effectively market vehicles and improve the profitability of their new and used vehicle sales".
The financial impact of the eCarList acquisition on DealerTrack's 2011 guidance will be provided in conjunction with the release of DealerTrack's results for the second quarter of 2011.
About DealerTrack (www.dealertrack.com)
DealerTrack's intuitive and high-value software solutions and services enhance efficiency and profitability for all major segments of the retail automotive industry, including dealers, lenders, OEMs, agents and aftermarket providers. DealerTrack, whose solution set for dealers is the industry's most comprehensive, operates the largest online credit application network in the United States, connecting approximately 17,000 dealers with more than 1,000 lenders. DealerTrack's Dealer Management System (DMS) provides dealers with easy-to-use tools and real-time data access to enhance their efficiency. DealerTrack's Inventory Solutions Group delivers inventory management and merchandising tools and services needed to accelerate used-vehicle turn rates and help increase profits for dealers. DealerTrack's Sales and F&I solutions allow dealers to streamline the entire sales process as they structure deals from a single integrated platform. Its Compliance solution helps dealers meet legal and regulatory requirements and protect their assets. DealerTrack also offers additional solutions for the automotive industry including electronic motor vehicle registration and titling applications, paper title storage, and digital document services. DealerTrack's family of companies also includes data and consulting service providers ALG and Chrome Systems. For more information, visit www.dealertrack.com.
Safe Harbor for Forward-Looking and Cautionary Statements
Statements in this press release regarding benefits to DealerTrack and its customers of the acquisition of eCarList and all other statements in this release other than the recitation of historical facts are forward-looking statements (as defined in the Private Securities Litigation Reform Act of 1995). These statements involve a number of risks, uncertainties and other factors that could cause actual results, performance or achievements of DealerTrack to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements.
Factors that might cause such a difference include: economic trends that affect the automotive retail industry or the indirect automotive financing industry including the number of new and used cars sold; reductions in auto dealerships; the impact of some vendors of software products for automotive dealers making it more difficult for DealerTrack's customers to use DealerTrack's solutions and services; security breaches, interruptions, failures and/or other errors involving DealerTrack's systems or networks; the failure or inability to execute any element of DealerTrack's business strategy, including selling additional products and services to existing and new customers; the integration of the eCarList acquisition and the expected benefits; DealerTrack's success in expanding its customer base and product and service offerings; and other risks listed in DealerTrack's reports filed with the Securities and Exchange Commission (SEC), including its most recent Annual Report on Form 10-K. These filings can be found on DealerTrack's website at www.dealertrack.com and the SEC's website at www.sec.gov. Forward-looking statements included herein speak only as of the date hereof and DealerTrack disclaims any obligation to revise or update such statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events or circumstances, except as required by law.
TRAK-E ###

text: Mark Brown

text: Elizabeth Besen

text: DealerTrack

text: eCarList

text: DealerTrack AAX, Inc.

text: DealerTrack

text: eCarList LLC

text: eCarList

text: eCarList

text: eCarList

text: DealerTrack

text: eCarList

text: DealerTrack

text: eCarList

text: eCarList

text: eCarList

text: DealerTrack

text: DealerTrack

text: DealerTrack

text: DealerTrack

text: DealerTrack

text: DealerTrack

text: DealerTrack

text: DealerTrack

text: DealerTrack

text: DealerTrack

text: DealerTrack

text: eCarList

text: DealerTrack

text: DealerTrack

text: DealerTrack

text: DealerTrack

text: DealerTrack

text: eCarList

text: DealerTrack

text: DealerTrack

text: DealerTrack

text: DealerTrack


text:
EX-99.1
36
ex99-1.htm
PRESS RELEASE
Perma-Fix
Completes Sale of Tulsa Industrial Facility
for
Approximately $1. 5 Million
ATLANTA
-June 3, 2008 - Perma-Fix Environmental Services, Inc. (NASDAQ:
PESI)
("Perma-Fix") has completed the previously announced sale of one of its
Industrial segment facilities located in Tulsa, Oklahoma, to A Clean Environment
Company, Inc. ("ACE") for approximately $1.5 million in cash, subject to certain
working capital adjustments during the third quarter of 2008, and the assumption
of certain liabilities. ACE is an environmental services company located in
Wilson, Oklahoma.
The
sale
of the Tulsa facility by Perma-Fix represents the third completed transaction
in
connection with Perma-Fix's plan to divest all or large part of its Industrial
segment. Perma-Fix has previously disclosed the completion of the sale of its
Maryland and Dayton, Ohio, facilities within its Industrial
segment.
About
Perma-Fix Environmental Services
Perma-Fix
is a national environmental services company, providing unique mixed waste
and
industrial waste management services. Perma-Fix has increased its focus on
the
nuclear services segment, which provides radioactive and mixed waste treatment
services to hospitals, research laboratories and institutions, numerous federal
agencies including DOE and the U.S. Department of Defense and nuclear utilities.
The Industrial segment provides hazardous and non-hazardous waste treatment
services for a diverse group of customers including Fortune 500 companies,
numerous federal, state and local agencies and thousands of smaller
clients.
Please
visit us on the World Wide Web at http://www.perma-fix.com.
Contacts:
Dr.
Louis F. Centofanti, Chairman and CEO
David
K. Waldman-US Investor Relations
Perma-Fix
Environmental Services, Inc.
Crescendo
Communications, LLC
(770)
587-5155
(212)
671-1020 x101
Herbert
Strauss-European Investor Relations
herbert@eu-ir.com
+43
316 296 31

text: Perma-Fix

text: Perma-Fix

text: Perma-Fix

text:
A Clean Environment
Company, Inc.

text: Perma-Fix

text: Perma-Fix

text: Perma-Fix

text: Perma-Fix

text: Perma-Fix

text: Perma-Fix

text: Louis F. Centofanti

text: Perma-Fix


text:
EX-99.2
5
ex99-2.htm
EXHIBIT 99.2
ex99-2.htm
Exhibit 99.2
For Immediate Release
Xplore
Closes
Purchase of
Motion Computing
Acquisition Provides Xplore
Most Comprehensive Portfolio of Rugged Tablet
s
Austin, Texas - April 1
7
, 2015 -
Xplore Technologies Corp. (NASDAQ: XPLR) ("Xplore" or the "Company"), a manufacturer of award-winning rugged tablet PCs, announced today the closing of its previously disclosed acquisition of substantially all of the assets of Motion Computing, Inc. and its subsidiaries ("Motion").
The transaction was effected through an asset purchase and sale agreement by and among Xplore, Motion and Square 1 Bank, Motion's senior secured lender. Xplore acquired Motion for approximately $9 million in cash, plus the assumption of approximately $7 million in net liabilities. Xplore consummated the transaction using proceeds from a new $15 million credit facility with Square 1 Bank.
Xplore intends to file a current report on Form 8-K on or about June 30, 2015 that will include Motion's audited financial statements, as well as historical pro forma financial information for the combined businesses.
The Company conducted a conference call at 4:30 pm EST on Thursday, April 16, 2015 to provide additional information on this transaction. A replay of the conference call is available until May 15, 2015, by calling 877-660-6853 from the United States or 201-612-7415 from outside the United States and entering conference ID number 13606316.
About Xplore Technologies®
Xplore Technologies Corp. has been a leading global provider of truly rugged tablets since 1996. Xplore tablets are among the most powerful and longest lasting in their class, withstand nearly any hazardous condition or environmental extreme, and feature competitive pricing and significant ROI. The company's products are sold on a global basis, with channel partners in the United States, Canada, Europe and Asia Pacific. Xplore Technologies' tablets are deployed across a variety of industries and sectors, such as energy, military operations, manufacturing, distribution, public services, public safety, government, and other areas with hazardous work conditions. For more information, visit the Xplore Technologies website at
www.xploretech.com
.
Xplore: For Investor Information Contact:
Chris Schreiber
Taglich Brothers
cs@taglichbrothers.com
(917) 445-6207
About Motion
Motion Computing® empowers organizations worldwide with technology solutions designed to optimize the performance of mobile workers. Building on a foundation of award-winning technical expertise and decades of industry experience, the Motion® team makes it their business to understand your business. Through industry-leading rugged tablet PCs, tailored accessories and services - Motion delivers mobile technology solutions customized to business workflows. Purposely built for vertical markets including field service, healthcare, utilities, construction, retail, public safety and first responders - Motion's suite of mobile technology solutions improves worker productivity, data accuracy and security, while enabling real-time decision making at the point-of-service. Customers report lower operational expenses, increased efficiency and enhanced customer service. Motion makes its solutions available through a global network of value added resellers and distributors.
Forward Looking Statements
This news release contains forward-looking statements that involve risks and uncertainties, which may cause actual results to differ materially from the statements made. When used in this document, the words "may", "would", "could", "will", "intend", "plan", "anticipate", "believe", "estimate", "expect" and similar expressions are intended to identify forward-looking statements. Such statements reflect Xplore's current views with respect to future events and are subject to such risks and uncertainties. Many factors could cause actual results to differ materially from the statements made including those factors detailed from time to time in filings made by Xplore with securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated or expected. Xplore does not intend and does not assume any obligation to update these forward-looking statements.

text: Xplore

text: Motion Computing

text: Xplore

text: Xplore Technologies Corp.

text: Xplore

text: Motion Computing, Inc.

text: Motion

text: Xplore

text: Motion

text: Motion

text: Xplore

text: Motion

text: Xplore

text: Xplore

text: Motion

text: Xplore Technologies Corp.

text: Xplore

text: Xplore

text: Motion

text: Motion Computing

text: Motion

text: Motion

text: Motion

text: Motion

text: Xplore

text: Xplore

text: Xplore


text:
EX-99.1
2
sykexhibit12172013.htm
EXHIBIT
syk 99.1
STRYKER COMPLETES ACQUISITION OF MAKO SURGICAL CORP.
Kalamazoo, Michigan - December 17, 2013 - Stryker Corporation (NYSE:SYK) announced today the completion of its previously announced acquisition of MAKO Surgical Corp., a pioneer in the advancement of robotic arm assisted surgery in orthopaedics.
"We're excited to welcome MAKO into our organization and combine their expertise in robotic arm assisted surgery with Stryker's innovations in joint reconstruction to further advance the growth of this compelling technology. The long-term potential offered by this technology platform holds the promise of transforming reconstructive surgery, increasing patient satisfaction and enhancing the experience for surgeons and hospitals", said Kevin A. Lobo, President and Chief Executive Officer.
As indicated in the September 25, 2013 press release, the transaction is expected to be dilutive to Stryker's adjusted earnings per share excluding acquisition and integration-related charges by approximately $0.10 - $0.12 in the first full year, neutral in year two and accretive thereafter. Additionally, the transaction is expected to be slightly accretive to adjusted cash earnings per share, excluding acquisition and integration-related charges in the first full year.
Stryker is one of the world's leading medical technology companies and is dedicated to helping healthcare professionals perform their jobs more efficiently while enhancing patient care. The Company offers a diverse array of innovative medical technologies, including reconstructive, medical and surgical, and neurotechnology and spine products to help people lead more active and more satisfying lives. For more information about Stryker, please visit www.stryker.com.
Contacts
For media inquiries please contact:
Yin Becker, Stryker Corporation, 201-831-5000 or yin.becker@stryker.com
For investor inquiries please contact:
Katherine A. Owen, Stryker Corporation, 269-385-2600 or katherine.owen@stryker.com
Forward-Looking Statements
This press release contains information that includes or is based on forward-looking statements within the meaning of the federal securities law that are subject to various risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in such statements. Such factors include, but are not limited to: weakening of economic conditions that could adversely affect the level of demand for our products; pricing pressures generally, including cost-containment measures that could adversely affect the price of or demand for our products; changes in foreign exchange markets; legislative and regulatory actions; unanticipated issues arising in connection with clinical studies and otherwise that affect U.S. Food and Drug Administration approval of new products; changes in reimbursement levels from third-party payors; a significant increase in product liability claims; the ultimate total cost with respect to the Rejuvenate and ABG II matter; the impact of investigative and legal proceedings and compliance risks; resolution of tax audits; the impact of the federal legislation to reform the United States healthcare system; changes in financial markets; changes in the competitive environment; our ability to integrate acquisitions, including the acquisition of MAKO Surgical Corp.; and our ability to realize anticipated cost savings as a result of workforce reductions and other restructuring activities. Additional information concerning these and other factors are contained in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

text: STRYKER

text: MAKO SURGICAL CORP.

text: Stryker Corporation

text: MAKO Surgical Corp.

text: Stryker

text: Kevin A. Lobo

text: Stryker

text: Stryker

text: Stryker

text: Stryker Corporation

text: Stryker Corporation

text: MAKO Surgical Corp.


text:
EX-99.1
8
dex991.htm
EXHIBIT 99.1
Exhibit 99.1
Exhibit 99.1
PAETEC Media Contact
Chris Muller
585.340.8218
christopher.muller@paetec.com
PAETEC Investor Contact
Pete Connoy
585.340.2649
peter.connoy@paetec.com
FOR IMMEDATE RELEASE
PAETEC Completes Acquisition of Cavalier Telephone
Acquisition solidifies PAETEC's position as one of the largest competitive telecom
providers in the United States as measured by revenue, markets served and fiber assets
FAIRPORT, N.Y. and RICHMOND, Va. - December 6, 2010
- PAETEC Holding Corp. (NASDAQ GS: PAET) today announced that it has completed its acquisition of privately-owned Cavalier Telephone
Corporation. As a result of the acquisition, PAETEC now has over 10,600 metro fiber-route miles, over 36,700 total fiber-route miles, and 1,178 collocations to support connectivity to enterprise businesses nationwide. Through close cooperation with
the FCC and a significant number of state regulatory agencies, the company was able to close this acquisition just 12 weeks from the initial announcement on September 13, 2010.
As part of the transaction, PAETEC acquired Cavalier's wholly owned subsidiary, Intellifiber Networks, Inc. Intellifiber includes a high capacity fiber network spanning approximately 16,600 route
miles and representing over $2 billion of investment by companies Cavalier acquired over the last decade. The expansive 11,947 route-mile intercity network spans the Midwest and Eastern U.S., as well as 4,681 route miles throughout several existing
PAETEC metro areas, allowing for broad connectivity options for customers. Intellifiber offers scalable network solutions for service provider, enterprise,
and government customers including private networks, low latency routing, SONET services, wavelengths, Ethernet, and data options.
"We are very pleased to close this acquisition of Cavalier Telephone in less than three months from signing the definitive agreement", said Arunas A. Chesonis, PAETEC chairman and CEO.
"Over the summer, we developed a dedicated cross-functional M&A team to facilitate the complex merger issues. That team, along with the diligent efforts of our regulatory, legal and financial staff, made this a dramatically quicker
process."
Additional information about the transaction will be contained in PAETEC's Current Report on Form 8-K to be filed with
the SEC.
About PAETEC
PAETEC (NASDAQ GS: PAET) is personalizing business communications for medium-sized and large businesses, enterprise organizations, and institutions across
the United States. PAETEC offers a comprehensive suite of IP, voice, data and Internet services, as well as enterprise communications management software, network security solutions, CPE, and managed services. For more information, visit
www.paetec.com.
2

text: PAETEC

text: PAETEC

text: PAETEC

text: Cavalier Telephone

text: PAETEC

text: PAETEC Holding Corp.

text:
Cavalier Telephone
Corporation

text: PAETEC

text: PAETEC

text: Cavalier

text: Intellifiber Networks, Inc.

text: Cavalier

text: PAETEC

text: Cavalier Telephone

text: PAETEC

text: PAETEC

text: PAETEC

text: PAETEC

text: PAETEC


text:
EX-99.1
3
exhibit99-1.htm
EXHIBIT 99.1
IntelGenx Corp. - Exhibit 99.1 - Filed by newsfilecorp.com
IntelGenx Announces Sale of
Forfivo XL
®
Royalty for $6 Million
Saint-Laurent, Canada - August 5, 2016
- IntelGenx
Corp., (TSXV: IGX) (OTCQX: IGXT), (the "Company" or "IntelGenx") today announced
that it has sold its royalty on future sales of Forfivo XL
®
to SWK
Holdings Corporation (SWKH.OB) ("SWK" or the "Company") for $6 million (CAD$8
million). Forfivo XL
®
(Bupropion extended-release) is the first 450
mg bupropion HCl tablet indicated for Major Depressive Disorder, approved by the
FDA.
Under the terms of the agreement, SWK will pay IntelGenx $6
million at closing. In return for, (i) 100% of any and all royalties (as defined
in the Edgemont Pharmaceuticals, LLC License Agreement) or similar royalty
amounts received on or after April 1, 2016, (ii) 100% of the $2 million
milestone payment upon Edgemont reaching annual net sales of $15 million, and
(iii) 35% of all potential future milestone payments. Patent protection for
Forfivo XL
®
in the United States expires in 2027 with an authorized
generic entering the market in January 2018.
"We are pleased to be able to monetize the Forfivo royalty
stream to provide IntelGenx with a non-dilutive source of cash to be used in
strengthening our balance sheet", said Dr. Horst G. Zerbe, President and CEO of
IntelGenx. "This is by far the largest influx of capital in the history of the
company. Our goal is to use the proceeds in advancing our pharmaceutical oral
film pipeline which we believe can bring significant long term returns to
shareholders. We are now completely focused on becoming a global leader in
pharmaceutical oral films".
"Our structured purchase of the IntelGenx royalty stream
reflects our commitment to provide creative financing solutions to life science
companies", said Winston Black, CEO of SWK Holdings Corporation.
About SWK Holdings Corporation:
SWK Holdings
Corporation is a specialized finance company with a focus on the global
healthcare sector. SWK partners with ethical product marketers and royalty
holders to provide flexible financing solutions at an attractive cost of capital
to create long-term value for both SWK's business partners and its investors.
SWK believes its financing structures achieve an optimal partnership for
companies, institutions and inventors seeking capital for expansion or capital
and estate planning by allowing its partners to monetize future cash flow with
minimal dilution to their equity stakes. Additional information on the life
science finance market is available on the Company's website at www.swkhold.com.
About IntelGenx:
IntelGenx is a leading oral drug
delivery company focused on the development and manufacturing of innovative
pharmaceutical oral films based on its proprietary VersaFilm
TM
technology platform. Established in 2003, the Montreal-based company is
listed on the TSX-V and OTC-QX.
IntelGenx highly skilled team provides comprehensive
pharmaceutical
s
services to pharmaceutical partners, including
R&D, analytical method development, clinical monitoring, IP and regulatory
services. IntelGenx state-of-the art manufacturing facility, established for the
VersaFilm
TM
technology platform, supports lab-scale to pilot and
commercial-scale production, offering full service capabilities to our clients. More
information is available about the company at: www.intelgenx.com.
Forward Looking Statements:
This document may
contain forward-looking information about IntelGenx' operating results and
business prospects that involve substantial risks and uncertainties. Statements
that are not purely historical are forward-looking statements within the meaning
of Section 21E of the Securities Exchange Act of 1934, as amended, and Section
27A of the Securities Act of 1933, as amended. These statements include, but are
not limited to, statements about IntelGenx' plans, objectives, expectations,
strategies, intentions or other characterizations of future events or
circumstances and are generally identified by the words "may", "expects,"
"anticipates", "intends", "plans", "believes", "seeks", "estimates", "could,"
"would", and similar expressions. All forward looking statements are expressly
qualified in their entirety by this cautionary statement. Because these
forward-looking statements are subject to a number of risks and uncertainties,
IntelGenx' actual results could differ materially from those expressed or
implied by these forward looking statements. Factors that could cause or
contribute to such differences include, but are not limited to, those discussed
under the heading "Risk Factors" in IntelGenx' annual report on Form 10-K, filed
with the United States Securities and Exchange Commission and available at
www.sec.gov, and also filed with Canadian securities regulatory authorities and
www.sedar.com. IntelGenx assumes no obligation to update any such
forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX Venture Exchange),
nor the OTCQX accepts responsibility for the adequacy or accuracy of this
release.
Source: IntelGenx Technologies Corp.
For more information, please contact:
Edward Miller
Director, IR and Corporate
Communications
IntelGenx Corp.
T: +1 514-331-7440 (ext. 217)
edward@intelgenx.com

text: IntelGenx Corp.

text: IntelGenx

text:
IntelGenx
Corp.

text: IntelGenx

text:
SWK
Holdings Corporation

text: SWK

text: SWK

text: IntelGenx

text: IntelGenx

text: Horst G. Zerbe

text: IntelGenx

text: IntelGenx

text: Winston Black

text: SWK Holdings Corporation

text: SWK Holdings Corporation

text:
SWK Holdings
Corporation

text: SWK

text: SWK

text: SWK

text: IntelGenx

text: IntelGenx

text: IntelGenx

text: IntelGenx

text: IntelGenx

text: IntelGenx

text: IntelGenx

text: IntelGenx

text: IntelGenx

text: IntelGenx

text: Edward Miller

text: IntelGenx Corp.


text:
EX-99.1
2
e615454_ex99-1.htm
Unassociated Document
Contact at Winthrop Realty Liquidating Trust
Carolyn Tiffany
Investor or Media Inquiries
Phone: (617) 570-4614; e-mail: ctiffany@firstwinthrop.com
FOR IMMEDIATE RELEASE
August 11, 2016
WINTHROP REALTY LIQUIDATING TRUST TO MAKE DISTRIBUTION OF $1.00 PER BENEFICIAL INTEREST
________________
One East Erie, Chicago, Illinois Property Sold-Waterfront Loan Satisfied
FOR IMMEDIATE RELEASE - BOSTON, MASSACHUSETTS, August 11, 2016-Winthrop Realty Liquidating Trust (the "Trust") announced today the sale of its One East Erie office property located in Chicago, Illinois. After satisfying all closing costs associated with the sale, the Trust received an aggregate of approximately $46.8 million from the sale. The amount received is consistent with Winthrop Realty Trust's most recently reported liquidation value attributable to this asset.
In addition, the $11.0 million mezzanine loan indirectly secured by Waterfront Plaza, Honolulu, Hawaii and held by the Trust's Concord Debt Holdings venture, in which the Trust holds a two-thirds interest, was satisfied in full. The amount received is consistent with Winthrop Realty Trust's most recently reported liquidation value attributable to this asset.
As a result of the sale of One East Erie and the payoff of the Waterfront mezzanine loan, the Trust's trustees have approved a liquidating distribution of $1.00 per common beneficial interest in the Trust payable in cash on or about August 23, 2016. For tax purposes, no gain or loss was recognized on the property sale or the loan payoff and the liquidating distribution is considered a return of capital.
__________________
About Winthrop Realty Liquidating Trust
Winthrop Realty Liquidating Trust was formed to continue the liquidation process of remaining assets held by Winthrop Realty Trust at August 5, 2016. The Trust's sole purpose is to continue to seek to sell these assets in an orderly fashion to maximize value to its beneficiaries. Subject to certain exceptions related to transfer by will, intestate succession or operation of law, interests in the Trust are not transferable, nor do beneficiaries have authority or power to sell or in any other manner dispose of their interest in the Trust. For more information about the Trust's remaining assets, please visit our web-site at
www.winthropreit.com
.

text: Winthrop Realty Liquidating Trust

text: WINTHROP REALTY LIQUIDATING TRUST

text: One East Erie

text: Winthrop Realty Liquidating Trust

text: Trust

text: One East Erie

text: Trust

text: Trust

text: Trust

text: Trust

text: Trust

text: One East Erie

text: Trust

text: Trust

text: Winthrop Realty Liquidating Trust

text: Winthrop Realty Liquidating Trust

text: Trust

text: Trust

text: Trust

text: Trust

text: Trust


text:
EX-99.6
10
ex99-6.htm
EX-99.6
Exhibit 99.6
Asure Software Expands Payroll Offering to Benefit Broker Community with Acquisition of Corporate Payroll Inc.
Austin, Texas, January 3, 2017 - Asure Software, Inc. (NASDAQ: ASUR), a leading provider of Human Capital Management (HCM) and Digital Workplace software, has acquired Corporate Payroll Inc., (CPI). Based outside Cleveland, in Solon, Ohio, CPI is a current reseller of Asure's HCM solution, which provides human resources solutions that enhance organizations, people, and profits through Payroll/HR Solutions.
With its extensive broker community, the acquisition of CPI creates a new channel for Asure's expansion into the Midwest. Asure will leverage CPI's referral network to provide new clients the tools necessary to ensure the success of their most valuable resources, their people.
"We are excited about of the acquisition of CPI, who is a current Asure HCM reseller (formerly Mangrove)", said Pat Goepel, CEO of Asure. "I am equally excited to be partnering with CPI CEO Jim Hopkins and his team. CPI along with our newly appointed Director of Benefit Sales, Matt Absher, will work together to grow our payroll offering to the benefit broker community. We expect this acquisition and partnership to be accretive to our overall P&L".
CPI clients will continue to receive the local expertise they have come to value and expect, but will now benefit from Asure's ability to provide the workforce and workplace management services and support of a larger organization.
Jim Hopkins, CPI CEO, said: "We are excited to partner with Asure Software as our clients are already aligned with them directly. By scaling with a larger organization like Asure, it will better enable us to elevate our services, grow our expertise, and offer more solutions for our clients. We are glad to be partnering with a like-minded service organization focusing on exceptional client experiences".
About Asure Software
Asure Software, Inc. (NASDAQ: ASUR) is headquartered in Austin, Texas with regional headquarters in London, England. Asure offers intuitive and innovative technologies that enable companies of all sizes and complexities to operate more efficiently. The company ensures a high-performing work environment by integrating its "keep it simple" solutions and expertise to more than 7,000 clients worldwide. Asure Software's suite of solutions range from HCM, workforce management solutions, time and attendance to workspace asset optimization and meeting room management solutions. For more information, please visit www.asuresoftware.com.
Asure Company Contact
Stacy Zellner
Telephone: 888-323-8835 x 3111
E-mail: szellner@asuresoftware.com
Asure Investor Contact
Matt Glover and Najim Mostamand
Liolios Group, Inc.
Telephone: 949-574-3860
E-mail: ASUR@liolios.com
###

text: Asure Software

text: Corporate Payroll Inc.

text: Asure Software, Inc.

text: Digital Workplace software

text: Corporate Payroll Inc.

text: CPI

text: CPI

text: CPI

text: CPI

text: CPI

text: Pat Goepel

text: CPI

text: CPI

text: CPI

text: CPI

text: Asure Software

text: Asure Software

text: Asure Software, Inc.

text: Asure Software


text:
EX-99
2
e19319ex99-1.txt
PRESS RELEASE
Exhibit 99
Press Release:
Contact: D. Ben Berry, Chairman, President and CEO, or
Mark A. Holmes, Senior Executive Vice President and CFO
Tel: (252) 334-1511
Gateway Financial Closes Purchase of
Three Provident Bank Branches
Elizabeth City, NC - October 18, 2004 - Gateway Financial Holdings, Inc.
(NASDAQ: GBTS), the holding company for Gateway Bank & Trust Co., announced
today that the Bank has completed its acquisition of three branches of Provident
Bank, a subsidiary of Provident Bankshares Corporation (Nasdaq: PBKS). The
branches, which are located in Elizabeth City, North Carolina, Emporia,
Virginia, and Suffolk, Virginia, opened today as branches of the Bank. The
addition of these three branches to Gateway's franchise increases its branch
network to 15 locations and adds approximately $128 million in deposits.
Based on conservative assumptions about the redeployment of the cash Gateway
received at closing into higher yielding loans and investment securities, it is
presently anticipated that the transaction will be slightly dilutive to earnings
in the fourth quarter of 2004 but will become accretive to earnings in the first
quarter of 2005 and beyond.
About Gateway
Gateway Financial Holdings, Inc., with $397 million in assets as of June 30,
2004, is a fast-growing financial services company headquartered in Elizabeth
City, North Carolina. It is the parent company of Gateway Bank & Trust Co., a
full-service community bank with a total of fifteen offices in North Carolina
and Virginia. The Bank also provides insurance through its Gateway Insurance
Services, Inc. subsidiary and brokerage services through its Gateway Investment
Services, Inc. subsidiary. The common stock of the Corporation is traded on the
Nasdaq National Market under the symbol GBTS. Please visit our web site at
www.gatewaybankandtrust.com.
Forward-Looking Statements
Statements contained in this news release, which are not historical facts, are
forward-looking statements, as that term is defined in the Private Securities
Litigation Reform Act of 1995. Amounts herein could vary as a result of market
and other factors. Such forward-looking statements are subject to risks and
uncertainties which could cause actual results to differ materially from those
currently anticipated due to a number of factors, which include, but are not
limited to, factors discussed in documents filed by the Company with the
Securities and Commission from time to time. Such forward-looking statements may
be identified by the use of such words as "believe", "expect", "anticipate",
"should", "planned", "estimated", and "potential". Examples of forward-looking
statements include, but are not limited to, estimates with respect to the
financial condition, expected or anticipated revenue, results of operations and
business of the Company that are subject to various factors which could cause
actual results to differ materially from these estimates. These factors include,
but are not limited to, failure to integrate the operations of the acquired
branches, general economic conditions, changes in interest rates, deposit flows,
loan demand, real estate values, and competition; changes in accounting
principles, policies, or
guidelines; changes in legislation or regulation; and
other economic, competitive, governmental, regulatory, and technological factors
affecting the Company's operations, pricing, products and services. The Company
undertakes no obligation to release revisions to these forward- looking
statements or reflect events or circumstances after the date of this release.
*end of release*

text: D. Ben Berry

text: Gateway Financial

text: Gateway Financial Holdings, Inc.

text: Gateway Bank & Trust Co.

text: Provident Bankshares Corporation

text: Gateway Financial Holdings, Inc.

text: Gateway Bank & Trust Co.


text:
EX-99.1
2
infn-10012018xex991.htm
EXHIBIT 99.1
Exhibit
Exhibit 99.1
Infinera Closes Acquisition of Coriant and Becomes One of the World's Largest Optical Network Equipment Providers
Sunnyvale, Calif. - October 1, 2018 - Infinera, provider of Intelligent Transport Networks, announces the closing of its acquisition of Coriant, a privately held global supplier of open network solutions for the largest global network operators. The acquisition positions Infinera as one of the largest vertically integrated optical network equipment providers in the world.
The closing was pursuant to the terms of the definitive unit purchase agreement previously announced by Infinera on July 23, 2018. In connection with the purchase of Coriant, Infinera issued 20,975,384 shares of its common stock and will pay an aggregate amount of cash consideration consisting of approximately $230 million, of which approximately $154 million was paid upon closing.
The acquisition is expected to significantly increase revenue while expanding Infinera's customer base to serve nine of the top 10 global network operators and the top six global internet content providers. The combination positions Infinera to deliver a powerful suite of innovative, end-to-end packet optical network solutions for communications service providers and internet content providers.
"This is an exciting day for Infinera. The acquisition of Coriant is a major milestone, expanding the scope of our vertical integration strategy across a powerful suite of packet optical solutions for our customers", said Tom Fallon, Infinera CEO. "The acquisition immediately strengthens our ability to serve a global customer base and accelerates delivery of the innovative solutions our customers demand".
Initial feedback from existing Infinera and Coriant customers has been positive. Highlights include:
.
"Coriant already delivers strong technical value across our network, and we expect a stronger Infinera that will enhance and satisfy the transport needs of the customers", said Cayetano Carbajo Martín, Telefónica Chief Technology Officer. "With the combined products and solutions from both companies, we look forward to more innovation from Infinera both for packet data and transmission".
.
"GTT's clients expect industry-leading, differentiated network infrastructure solutions to ensure their networks are reliable and secure", said Paul Monteiro, SVP, Operations and Engineering at GTT. "We welcome Infinera's acquisition of Coriant which enables Infinera to provide a broader range of high-performance network infrastructure capabilities".
.
"The consolidation of both companies marks a significant milestone for the industry. As two industry pioneers, we believe strongly in their potential to deliver game-changing, innovative technology that will power the future of networks", said Buddy Bayer, Chief Network Officer at Windstream.
.
"We are excited to see Infinera's acquisition of Coriant and anticipate that not only will we benefit from their combined innovation, but also their enhanced customer service as we invest in expanding our network footprint over the next five years", said Conrad Mallon, Chief Technical Architect at SSE Enterprise Telecoms. "It will be interesting to see how the orchestration and software strategy of the combined organizations develops and how they contribute to the world of SDN and NFV".
Infinera's acquisition of Coriant adds approximately 2,100 employees, over 1,600 patents and more than 600 customers globally to Infinera. Integration planning for the combined company is on schedule.
Additional Resource:
.
Infinera Scales for Next Wave of Global Network Spending - Announces Intent to Acquire Coriant and Preliminarily Reports Strong Q2 Performance
Contacts:
Media:
Anna Vue
Investors:
Jeff Hustis
Tel. +1 (916) 595-8157
Tel. +1 (408) 213-7150
avue@infinera.com
jhustis@infinera.com
About Infinera
Infinera (NASDAQ: INFN) provides Intelligent Transport Networks, enabling carriers, cloud operators, governments and enterprises to scale network bandwidth, accelerate service innovation and automate optical network operations. Infinera's end-to-end packet-optical portfolio is designed for long-haul, subsea, data center interconnect and metro applications. To learn more about Infinera visit www.infinera.com, follow us on Twitter @Infinera and read our latest blog posts at blog.infinera.com.
Infinera and the Infinera logo are registered trademarks of Infinera Corporation.
This press release contains certain forward-looking statements based on current expectations, forecasts and assumptions that involve risks and uncertainties. Such forward-looking statements include, without limitation, Infinera's ability to deliver a powerful suite of innovative, end-to-end packet optical network solutions; and Infinera's expectations regarding the integration of the combined company. These statements are not guarantees of results and should not be considered as an indication of future activity or future performance. Actual results may vary materially from these expectations as a result of various risks and uncertainties. These risks and uncertainties include, but are not limited to, the following: Infinera's ability to achieve the synergies and value creation contemplated by the acquisition; the combined company's ability to promptly and effectively integrate the businesses of Infinera and Coriant; the diversion of management time on issues related to the integration; changes in laws or regulations; the risks of customer and employee loss and business disruption; increased competitive pressures and solicitations of customers and employees by competitors; the difficulties and risks inherent with entering new markets; and changes in general economic conditions. For additional information concerning factors that could cause actual conditions, events or results to materially differ from those described in the forward-looking statements, please refer to the factors contained in the risk factors section of Infinera's most recent Quarterly Report on Form 10-Q, filed with the SEC on August 8, 2018, as well as in Infinera's future Quarterly Reports on Form 10-Q, Annual Reports on Form 10-K and other filings that Infinera makes with the SEC. Infinera assumes no obligation to, and does not currently intend to, update any such forward-looking statements.

text: Infinera

text: Coriant

text: Infinera

text: Coriant

text: Infinera

text: Infinera

text: Coriant

text: Infinera

text: Infinera

text: Infinera

text: Infinera

text: Coriant

text: Infinera

text: Infinera

text: Coriant

text: Coriant

text: Infinera

text: Infinera

text: Infinera

text: Coriant

text: Infinera

text: Infinera

text: Coriant

text: Infinera

text: Coriant

text: Infinera

text: Infinera

text: Coriant

text: Infinera

text: Infinera

text: Infinera

text: Infinera

text: Infinera

text: Infinera

text: Infinera

text: Infinera

text: Infinera

text: Infinera

text: Infinera

text: Coriant

text: Infinera

text: Infinera

text: Infinera

text: Infinera


text:
EX-99.1 CHARTER
2
ex991.htm
ex991.htm -- Converted by SEC Publisher, created by BCL Technologies Inc., for SEC Filing
FOR IMMEDIATE RELEASE
Contact:
Media Relations:
Rick Swagler, (205) 801-0105
or
Investor Relations:
List Underwood, (205) 801-0265
Regions and AmSouth Complete Merger
BIRMINGHAM, Ala., Nov. 4, 2006 - Regions Financial Corp. (NYSE: RF) announced today that it has completed its merger with AmSouth Bancorporation (NYSE: ASO).
"This creates a top 10 U.S. bank holding company with leading positions in some of the fastest growing markets in the United States and an even broader range of products, services and locations for our 5 million customer households", said Jackson W. Moore, chairman of Regions' Board of Directors.
"With the combination of these two great companies we have redoubled our commitment to providing great service to our customers and forming strong relationships with our communities", said Dowd Ritter, president and chief executive officer of Regions and the former chairman, president and chief executive officer of AmSouth.
Customers of the new Regions will have immediate, free access to Regions and AmSouth's combined 2,800 ATMs for cash withdrawals. Merger integration teams formed earlier this year are continuing their work, and conversion of AmSouth branches and other operations will begin in mid-2007. Customers will be notified in advance if there are any changes to their banking relationships, however the company's goal is to make the process as invisible and seamless as possible for customers.
AmSouth and Regions announced plans to merge in May 2006, and shareholders of each company approved the transaction in October.
About Regions
Regions Financial Corporation is a member of the S&P 100 Index and, with more than $140 billion in assets, one of the nation's largest full-service providers of consumer and commercial banking, trust, securities brokerage, mortgage and insurance products and services. Regions serves customers in 16 states across the South, Midwest and Texas, and
through its subsidiary, Regions Bank, operates some 2,000 AmSouth and Regions banking offices and a 2,800-ATM network. Its investment and securities brokerage, trust and asset management division, Morgan Keegan & Company Inc., provides services from over 300 offices. Additional information about Regions and its full line of products and services can be found at
www.regions.com
.

text: Regions Financial Corp.

text: AmSouth Bancorporation

text: Jackson W. Moore

text: Dowd Ritter


text:
EX-99.1
5
sfbcpharmanetclosingreleasef.htm
PRESS RELEASE
BP53882 -- SFBC International -- Exhibit 99.1
Exhibit 99.1
Contact:
Ana Lopez
Evan Smith, CFA / Erica Pettit
SFBC International
Financial Dynamics
305-895-0304
212-850-5606 / 212-850-5614
SFBC International Announces Completion of Merger with PharmaNet
- - -
Merger Positions SFBC as Top 10 Global Provider of Comprehensive Phase I-IV Drug Development Services
MIAMI - December 22, 2004 - SFBC International, Inc. (NASDAQ: SFCC)
, a provider of specialized drug development services to global and specialty pharmaceutical, biotechnology and generic drug companies, announced today that it has completed its merger with PharmaNet, Inc., a private international drug development company headquartered in Princeton, NJ, which was previously announced on November 3, 2004. The combined entity will provide one of the most comprehensive Phase I-IV drug development service offerings across North and South America, Europe, Asia and Australia with plans to expand its presence in Central/Eastern Europe and Asia, including Japan and Singapore.
Under the terms of the agreement, SFBC purchased 100% of the stock of PharmaNet for approximately $248.6 million in cash, including PharmaNet's estimated working capital. SFBC financed the transaction with approximately $134 million of cash from its balance sheet and $125 million drawn from new $160 million senior secured credit facilities.
All 15 key PharmaNet executives signed multi-year employment agreements with SFBC and used a portion of the merger consideration to purchase SFBC common stock or acquire SFBC options. SFBC received approximately $8.9 million from the sale of common stock at $34.33 per share. Mr. Jeffrey P. McMullen will remain President and Chief Executive Officer of PharmaNet and will join the executive management team of SFBC. Mr. McMullen is expected to join SFBC's Board of Directors at SFBC's next Annual Meeting of Stockholders.
The $160 million senior secured credit facilities, which were syndicated by UBS Securities LLC serving as lead arranger and sole bookrunner, consist of a $120 million Term Loan and a $40 million revolving line of credit, which replaced the Company's previous $25 million line of credit. An aggregate of $125 million was drawn under the facilities at closing. SFBC's existing $8.7 million mortgage on its Miami facility was paid off. SFBC now has total senior secured debt of $125 million and total debt, including the Senior Convertible Notes, of approximately $275 million.
"This merger is an exceptional strategic fit, resulting in SFBC becoming a global top 10 contract research organization with a diversified service offering, customer mix and geographic presence", stated Arnold Hantman, Chief Executive Officer of SFBC. "We look forward to building upon our current focus to expand our services and global reach to meet the growing needs of branded pharmaceutical, biotechnology and generic drug companies worldwide. We are confident that this merger will offer a range of opportunities to expand our presence with existing clients as well as enable us to attract new clients given the increased size and scope of our resources and capabilities".
Dr. Lisa Krinsky, Chairman and President of SFBC, commented, "We are extremely pleased to complete this combination, which we believe firmly establishes SFBC as a leader in the contract research marketplace. This merger creates a stronger platform for potential growth in the coming years by providing our clients with access to 2,000 employees in 25 countries on five continents. Our clients are interested in developing new drugs more quickly and in a more cost effective manner, while improving the quality and level of testing to ensure the safety and efficacy of the drugs when they come to market. This merger will enable us to provide optimal site selection, timely patient recruitment and the efficient conduct of complex worldwide clinical trials. We welcome PharmaNet's employees to SFBC and look forward to serving our clients and a broader market going forward. This merger will further enable SFBC to take a leadership role in delivering the highest quality drug development services to our clients worldwide".
Jeffrey P. McMullen, President and Chief Executive Officer of PharmaNet, stated, "The closing of the merger is a significant milestone that provides PharmaNet with a unique opportunity to combine forces with a highly successful company within the contract research industry and create a much stronger organization given the highly complementary nature of our businesses. We're very excited about joining SFBC because we believe the company has the resources and commitment necessary to support our combined growth strategy. With the global PharmaNet team remaining in place combined with the support of SFBC, we are confident we can continue to build on our record of success. I look forward to playing an integral role in the future success of SFBC".
Jefferies & Company acted as financial advisor to SFBC in connection with this transaction. UBS Investment Bank acted as financial advisor to PharmaNet.
About SFBC International, Inc.
SFBC International, Inc. is a global leader in providing early and late stage drug development services with one of the broadest and highest quality service offerings to support the growing drug development needs of the pharmaceutical, biotechnology, medical device and generic drug industries around the world. The company has more than 30 offices located in North America, South America, Europe, India, and Australia. In early clinical development services, SFBC specializes primarily in the areas of Phase I clinical trials and bioanalytical laboratory services, including early clinical pharmacology. The company also offers clinical development expertise in the following areas: strategic planning protocol/CRF design, consulting, project management, site selection and management, trial monitoring, information technology including electronic
data capture, data management and biostatistics, quality control/assurance, late-stage services and regulatory affairs. Additional information is available at the Company's website, www.sfbci.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act") including PharmaNet's expansion plans; the merger providing SFBC the ability to expand its presence and attract new clients; the anticipated positive effects the merger may have on SFBC, by creating a stronger platform for potential growth; providing SFBC with the ability to provide optimal site selection, timely patient recruitment, and the efficient conduct of complex worldwide clinical trials; its ability to create a stronger organization; and SFBC's continuing to build on its record of success. Additionally words such as "seek", "intend", "believe", "plan", "estimate", "expect", "anticipate" and other similar expressions are forward-looking statements within the meaning of the Act. Some or all of the results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include, but are not limited to, SFBC's ability to integrate PharmaNet, its clients and its employees or to achieve the benefits anticipated by the merger; regulatory changes; cancellation of contracts; changes affecting the clinical research industry; a reduction of outsourcing by pharmaceutical and biotechnology companies; factors which affect the profitability of SFBC's clients including drug safety issues, our ability to compete internationally in attracting pharmaceutical companies in order to develop additional business; our clients' ability to provide the drugs and medical devices used in our clinical trials; and the economic climate nationally and internationally as it affects drug development operations. Further information on the Company's risk factors is contained in the Company's Form 10-K and other filings with the Securities and Exchange Commission.
# # #

text: SFBC International

text: SFBC International

text: SFBC International

text: PharmaNet

text: SFBC

text: SFBC International, Inc.

text: PharmaNet, Inc.

text: SFBC

text: PharmaNet

text: PharmaNet

text: SFBC

text: PharmaNet

text: SFBC

text: SFBC

text: SFBC

text: SFBC

text: PharmaNet

text: SFBC

text: SFBC

text: SFBC

text: UBS Securities LLC

text: SFBC

text: SFBC

text: SFBC

text: Arnold Hantman

text: SFBC

text: Lisa Krinsky

text: SFBC

text: SFBC

text: PharmaNet

text: SFBC

text: SFBC

text: PharmaNet

text: PharmaNet

text: SFBC

text: PharmaNet

text: SFBC

text: SFBC

text: Jefferies & Company

text: SFBC

text: UBS Investment Bank

override: organization

text: PharmaNet

text: SFBC International, Inc.

text: SFBC International, Inc.

text: SFBC

text: PharmaNet

text: SFBC

text: SFBC

text: SFBC

text: SFBC

text: SFBC

text: PharmaNet

text: SFBC


text:
EX-99.1
4
tm2011831d1_ex99-1.htm
EXHIBIT 99.1
Exhibit 99.1
WPX Energy, Inc.
(NYSE:WPX)
www.wpxenergy.com
DATE:
March 6, 2020
MEDIA CONTACT:
Kelly Swan
(539) 573-4944
INVESTOR CONTACT:
David Sullivan
(539) 573-9360
WPX Completes Acquisition of Felix Energy
Shareholders overwhelmingly approve transaction
TULSA, Okla. - WPX Energy (NYSE: WPX) has completed its previously announced acquisition of Felix Energy, which has operations
in the eastern portion of the Permian's Delaware Basin.
The acquisition was overwhelmingly approved by WPX shareholders
at a special meeting held on March 5, 2020, where more than 99.6 percent of votes cast were in favor of the transaction.
"I want to thank the Felix team for working with us to
complete the transaction a month ahead of schedule while still hitting our expectations for production at the time of closing,"
said WPX Chairman and Chief Executive Officer Rick Muncrief.
"We remain absolutely convinced about the accretive nature
of the transaction and the outstanding quality of these assets. They overlie a tremendous resource that clearly gives us the means
for accelerating our ability to achieve our five-year targets for shareholders", Muncrief added.
As expected, Felix was producing 60 MBoe/d (70% oil) at the
close of the transaction. Including these assets, WPX now produces more than 150,000 barrels per day of oil from its operations
in the Delaware and Williston basins.
Upon close, an entity controlled by EnCap Investments L.P. -
the financial sponsor for Felix - received consideration of approximately 153 million shares of WPX stock and $900 million
in cash.
Along with the close, WPX added two representatives from EnCap
- D. Martin Philips and Douglas E. Swanson, Jr. - to its board of directors effective immediately.
"We're excited to add Marty and Doug to our board.
Their considerable experience in industry and their private equity backgrounds adds a unique perspective to WPX and how we can
further create value as a company", said Muncrief.
Barclays and Tudor, Pickering, Holt & Co. acted as financial
advisors to WPX on the transaction. Weil, Gotshal & Manges LLP served as legal advisor to WPX.
Jefferies LLC acted as financial advisor to Felix on the transaction.
Vinson & Elkins LLP served as legal advisor to Felix.
About WPX Energy, Inc.
WPX is an independent energy producer with core positions in
the Permian and Williston basins. The company built its Permian Basin position through acquisitions of RKI Exploration & Production,
Panther Energy and Felix Energy, along with the formation of a midstream joint venture with Howard Energy Partners.
# # #
This press release includes "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical
facts, included in this press release that address activities, events or developments that the company expects, believes or anticipates
will or may occur in the future are forward-looking statements. Such statements are subject to a number of assumptions, risks
and uncertainties, many of which are beyond the control of the company. Statements regarding future drilling and production are
subject to all of the risks and uncertainties normally incident to the exploration for and development and production of oil and
gas. These risks include, but are not limited to, the volatility of oil, natural gas and NGL prices; uncertainties inherent in
estimating oil, natural gas and NGL reserves; drilling risks; environmental risks; and political or regulatory changes. Investors
are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ
materially from those projected in the forward-looking statements. The forward-looking statements in this press release are made
as of the date of this press release, even if subsequently made available by WPX Energy on its website or otherwise. WPX Energy
does not undertake and expressly disclaims any obligation to update the forward-looking statements as a result of new information,
future events or otherwise. Investors are urged to consider carefully the disclosure in our filings with the Securities and Exchange
Commission, available from us at WPX Energy, Attn: Investor Relations, P.O. Box 21810, Tulsa, Okla., 74102, or from the SEC's
website at
www.sec.gov
.

text: WPX Energy

text: WPX

text: WPX

text: Felix Energy

text: WPX Energy

text: WPX

text: Felix Energy

text: WPX

text: WPX

text: WPX

text: EnCap Investments L.P.

text: WPX

text: WPX

text: WPX

text: Barclays

text: Tudor, Pickering, Holt & Co.

text: WPX

text: Weil, Gotshal & Manges LLP

text: WPX

text: Jefferies LLC

text: Vinson & Elkins LLP

text: WPX Energy

text: WPX

text: Felix Energy

text: WPX Energy

text: WPX Energy

text: WPX Energy